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relatively short term, the stimulation led to reduction
in her torticollis and a better ability to walk.
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ABSTRACT
Background: The analysis of coverage depth in next-
generation sequencing data allows the detection of gene
dose alterations. We explore the frequency of such struc-
tural events in a Spanish cohort of sporadic PD cases.
Methods: Gene dose alterations were detected with the
eXome-Hidden Markov Model (XHMM) software from
depth of coverage in resequencing data available for 38
Mendelian and other risk PD loci in 394 individuals (249
cases and 145 controls) and subsequently validated by
quantitative PCR.
Results: We identified 10 PD patients with exon dosage
alterations in PARK2, GBA-GBAP1, and DJ1. Additional
functional variants, including 2 novel nonsense mutations
(p.Arg1552Ter in LRRK2 and p.Trp90Ter in PINK1), were
confirmed by Sanger sequencing. This combined
approach disclosed the genetic cause of 12 PD cases.
Conclusions: Gene dose alterations related to PD can
be correctly identified from targeting resequencing
data. This approach substantially improves the detec-
tion rate of cases with causal genetic alterations. VC
2016 The Authors. Movement Disorders published by
Wiley Periodicals, Inc. on behalf of International Parkin-
son and Movement Disorder Society.
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Next-generation sequencing (NGS) technologies
such as whole-genome, whole-exome, and custom tar-
geting sequencing strategies are increasingly being
used to understand the genetic factors underlying both
common and rare neurological disorders.1,2 Notably,
the recent advent of the NGS technologies has been
accompanied by the implementation of new bioinfor-
matic tools to detect copy number variants (CNVs)
from the depth of read mapping, even after applying
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specific targeted enrichment.3-7 Most of these new
tools are based on the assumption that differences in
the depth of coverage among specific genomic regions
and across multiple samples can be used as an indica-
tor of the relative number of copies, resulting in a
semiquantitative estimation of CNVs. However, as far
as we know, this approach has never been attempted
in PD.
The main aim of this study was to explore whether
CNVs help to explain some sporadic PD patients in
which no causative point mutations are found. In
particular, we used our own resequencing data of 38
PD-associated genes in 249 PD cases and 145 unre-
lated controls of European ancestry8 to study the
presence of structural variants predicted by eXome-
Hidden Markov Model (XHMM) software (https://
atgu.mgh.harvard.edu/xhmm/), which was specifically
developed to recover information on copy number
variation from normalized read depth data obtained
from targeted sequencing experiments.3 Subsequently,
all the predicted CNVs were validated through quan-
titative polymerase chain reaction (PCR). Moreover,
detailed frequencies for all potentially functional
exon dose alterations detected here and for previous-
ly described pathogenic single nucleotide polymor-
phisms (SNPs) and indels in the same resequencing
dataset are provided to understand their relative rele-
vance in PD.
Methods
Participants and Targeted Resequencing Data
Targeted resequencing data from 394 individuals
including 249 idiopathic PD cases and 145 unrelated
controls of European origin were compiled from Spa-
taro et al. (2015).8 Details on eligibility criteria, clini-
cal and demographic features of PD patients and
targeting resequencing design are available in Appen-
dix 1 (Supplementary Data).
Coverage and Detection of CNVs
The mean coverage per target and sample was
49.39X, and 91% of the target bases were covered at
15X depth.8 The detection of CNVs was performed
with the XHMM software, which uses principal com-
ponent analysis normalization and a hidden Markov
model to detect and genotype CNVs from normalized
read-depth data from targeted sequencing experi-
ments.3 Phred-scaled quality scores for the CNV
events in the inferred intervals ranged from 30 to 99,
with a mean of 80 (see Table S1). Gene dose altera-
tions in Mendelian PD genes were then subsequently
validated by quantitative PCR (see details in Appendix
2 in the Supplementary Data).
PCR and Sanger Sequencing Validation
Analysis
Frameshift deletions and stop gain mutations within
the PARK2, LRRK2 and PINK1 genes plus genomic
rearrangements around the GBA-GBAP1 region were
confirmed by PCR and Sanger sequencing analyses
(see details in Appendix 3 in the Supplementary Data).
Collapsing Tests
The potential enrichment of exon dosage alterations
was tested in the whole set of cases and controls using
the full list of CNVs reported in Table S1. CNV enrich-
ment was performed with the VariantTools package
(http://varianttools.sourceforge.net/), which includes up
to 12 different collapsing tests.9
Results
Our study of structural genetic alterations across the
38 PD-associated genes previously sequenced through
NGS8 disclosed a total of 11 structural variants in the
PARK2, GBA, and DJ1 genes, affecting 10 of 249 PD
cases. All of these genomic alterations were predicted
by the XHMM sofware3 (see details in Table S1) and
were subsequently validated by quantitative PCR (Fig-
ure 1 and Figure S1). CNVs were also detected in 2 of
145 controls in a heterozygous state for the recessive
gene PARK2 and the GBA-GBAP1 region. The clini-
cal features of the PD samples in which structural var-
iants were found are provided in Appendix 1
(Supplementary Data). Additional functional sequence
alterations detected in the same dataset are listed in
Table 1 (see Table S2 for complete genotypes).
Structural Variants in the PARK2 Gene
We identified 4 different exon deletions and 1 exon
duplication in the PARK2 gene, affecting a total of 6
PD cases (Figure 1A). All of them have already been
described in PD cases.10,11 The 2 largest PARK2 dele-
tions spanned from exon 3 to 6 and from exon 2 to 4
and were found in heterozygosis in Cas241 and
Cas20, respectively. These 2 PD cases are examples of
compound heterozygotes because both individuals also
present different frameshift mutations in exon 2, caus-
ing a premature stop codon: Cas241 is heterozygote
for a dinucleotide deletion (p.Gln34Argfs), whereas
Cas20 is hemizygote for a single-nucleotide deletion
(p.Asn52Metfs; see Table 1, Table S2, and Figure S2).
The PARK2 deletion comprising exons 3 to 4 was
found in 2 different PD cases: Cas57, which is homo-
zygote for the deletion, and Cas246, which is an addi-
tional PARK2 compound heterozygote also carrying
the p.Asn52Metfs mutation. Finally, Cas232 is found
homozygote for a PARK2 deletion affecting exon 2,
and Cas148 is homozygote for a duplication affecting
exon 3. As expected, early age at onset (before 45
S P A T A R O E T A L
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years of age) was found in 4 of the 6 patients with
structural variants in PARK2.
Structural Variants in the GBA-PGBA1 Region
The high homology between GBA and its neighbor-
ing pseudogene (GBAP1), which share 96% of
sequence identity, not only explains several gene-
pseudogene rearrangements and gene-conversion
events12 but also complicates the analysis of the whole
region.13 Our analysis disclosed 4 individuals
presenting CNVs along the GBA-GBAP1 region (see
Figure 1B). Cas103, which has already been described
in Seto-Salvia et al. (2012),14 is heterozygote for a
recombinant deletion known as the Rec-Ncil allele
(where GBAP1 exons 1 to 10 and GBA exons 11 and
12 are deleted). In contrast, Cas211, Cas62, and
Cas136 are heterozygotes for 2 different duplications
along the same region. Because exons 11 and 12 in
the gene and the pseudogene are nearly identical, we
could not verify by quantitative PCR the exact limits
of the GBA-GBAP1 rearrangements detected (Figure
FIG. 1. Detection of copy number variation: (A) PARK2 gene, (B) GBA-GBAP1 region, and (C) DJ1 gene. In the upper panel, sequencing depth of
coverage for those samples inferred to carry copy number variants by the eXome-Hidden Markov Model (XHMM) software (https://atgu.mgh.har-
vard.edu/xhmm/) is indicated in colors along each exon; the color matches that of the individual label on the Y axis of the bottom panel. In all other
samples, the gray background represents sequencing depth of coverage. In the bottom panel, a schematic representation of the corresponding vali-
dated copy number variants is presented for each gene. Red bars, deletion; light blue bars, duplication; black diamonds, frameshift indels. The bot-
tom track represents a schematic representation of the gene structure.
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1B). Subsequent PCR and sequencing analysis allowed
us to confirm that Cas211 is heterozygote for the
reciprocal product of the Rec-Ncil deleted allele (exon
11 and 12 of the GBA gene and GBAP1 exons 1 to
10 are duplicated), whereas Cas62 and Cas136 are
heterozygotes for a duplication affecting the
30unstranslated region of the GBA gene and most of
the GBAP1 pseudogene (see details in Figure S3 and
Table S3). In addition to the GBA-GBAP1 duplication
rearrangement, Cas62 also carries the p.Asp370Ser
mutation described to increase risk for late-onset PD15
and known to be the most common causal mutation
for Gaucher’s disease in Ashkenazi Jews16 in a hetero-
zygous state (Table S2).
Structural Variants in the DJ1 Gene
Among all analyzed participants, only 1 PD patient
(Cas136) carried a heterozygous deletion comprising
the whole exon 4 of the DJ1 gene (Figure 1C). As far
as we are aware, this alteration has never been
reported before.10,11 Interestingly, the same individual
is also heterozygote for 1 duplication in the GBA-
GBAP1 region. Therefore, Cas136 could be a particu-
lar case of a double heterozygote for genomic
rearrangements occurring in 2 different PD loci.
Other Functional Mutations and
Enrichment of Rare Variation
Besides the detected structural variants, other func-
tional alterations (including several known PD
Mendelian mutations) had been previously detected in
the same dataset.8 Frequencies and details are presented
in Table 1 and Appendix 4 (Supplemental Data). Here,
we further validated particular genotypes by Sanger
sequencing in some PD cases to confirm genotypes in
regions with low coverage depth as well as novel poten-
tial causative variants. Notably, we confirmed the iden-
tification of 2 stop-gain mutations, to our knowledge
previously unreported, having checked the
PDmutDB,10,11 1000 Genomes Project,17 ExAC data-
base (http://exac.broadinstitute.org/, accessed April 26,
2016) and the dbSNP database18: p.Arg1552Ter in
LRRK2, which was found in 1 heterozygote carrier
(Cas55), and p.Trp90Ter in PINK1, which was found
in homozygosis (Cas154) and could also represent a
new causal variant for PD (see Figure S2).
In the same dataset, we have previously shown that
PD cases displayed significantly higher proportions of
rare (minor allele frequency (MAF) <1%) code-
altering (nonsynonymous SNPs, nonsense mutations,
and coding indels) variants than controls on Mende-
lian genes.8 Notably, when performing the same type
of collapsing analyses, considering only the exon dos-
age alterations identified here, PD cases also show sig-
nificant enrichment of CNV in PD Mendelian genes
when compared with controls (P value <.05 in 10 of
12 tests; Figure S4).
Discussion
Our analysis demonstrates the usefulness of NGS for
discovering different types of variants with a potential
TABLE 1. Summary of pathogenic alterations found in Mendelian genes related to PD.
Gene Mutation type DNAchange Proteinchange
Cases
(2N 5 498)
Controls
(2N 5 290) Sample ID (coverage)
PARK2 Missense c.802G>A1 p.Arg234Gln 3 0 Cas74 (58), Cas172(126), Cas214 (75)
(M Recessive) Frameshift c.154delA2 p.Asn52Metfs 3 1 Cas211 (31), Cas246ab (32),
Cas20ab(30), Con142(45)
Exon deletion Ex3-4del 3 0 Cas57c (0)d, Cas246 (20)d
Exon deletion Ex2del 2 0 Cas232c (0)d
Missense c.1244C>A3 p.Thr415Asn 1 0 Cas211 (76)
Missense c.574A>C4 p.Met192Leu 1 0 Cas76 (72)
Exon deletion Ex2-4del 1 0 Cas20 (34)d
Exon deletion Ex3-6del 1 0 Cas241 (24)d
Exon duplication Ex3dup 2 0 Cas148c (149)d
Frameshift c.220-221insGT5 p.Trp74Cysfs 1 0 Cas11 (29)
Frameshift c.101-102delAG6 p.Gln34Argfs 1 0 Cas241ab (25)
LRRK2
(M Dominant)
Missense c.6055G>A7 p.Gly2019Ser 3 0 Cas213 (126), Cas226 (39),
Cas113 (108)
Stop gain c.4654C>T8 p.Arg1552Ter 1 0 Cas55a (81)
DJ1 Exon deletion Ex4del 1 0 Cas136 (36)d
(M Recessive)
PINK1 Stop gain c.270G>A8 p.Trp90Ter 2 0 Cas154ac (2)
(M Recessive) Stop gain c.1366C>T9 p.Gln456Ter 1 0 Cas194 (30)
GBA RecNcil 1 0 Cas103 (61)d
1rs144032774 (C/T), 2rs754809877 (T/-), 3rs778125254 (G/T), 4rs9456735 (T/G), 5rs746646126 (-/CA), 6rs55777503 (CT/-), 7rs34637584 (G/A), 8Not reported
before, 9rs45539432 (C/T), aConfirmed with Sanger sequencing, bHemizygous, cHomozygous, dAverage coverage across duplication/deletion. Abbreviations:
2N, number of chromosomes.
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role in human disease. Among the detected inactivating
variants, we not only report point mutations and small
indels but also different exon dosage variants already
known to be involved in PD aetiology. Notably, all
predicted CNVs were subsequently confirmed by quan-
titative PCR, suggesting that the analysis of coverage
from resequencing data across multiple individuals pro-
vides valuable information for the identification of
exon dosage variants. It should be noted, however, that
the sensitivity of the XHMM software could not be
evaluated with this research design and that our study
was focused on a limited set of candidate genes. Thus,
an unknown number of CNVs could remain undiscov-
ered in this set of patients.
Whereas the analysis of functional SNP variation
and indels in Mendelian genes related to PD allowed
us to identify putative causative variants for 6 PD
cases (Cas211, Cas213, Cas226, Cas113, Cas55, and
Cas154), the joint analysis of these inactivating var-
iants, together with the exon dose alterations detected
here, probably helps to explain the disease phenotype
of 6 additional PD cases (Cas246, Cas20, Cas57,
Cas232, Cas148, Cas241) in our Spanish cohort of 249
PD cases (2.4%). Thus, as demonstrated in this dataset,
CNVs in the form of exon dose alterations are at least
as important as indels and other functional SNP varia-
tions in PD Mendelian genes when explaining the phe-
notype of apparently sporadic PD cases. Given the
recognized role of structural variants in several neuro-
degenerative disorders and because many NGS-based
projects with large numbers of individuals are currently
underway to study rare and common variant associa-
tion, efforts should be made to integrate the analysis of
potential CNVs in these new datasets.
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